laitimes

A new breakthrough in the fight against AIDS: two shots a year, 100% effective? Monday Jian

A new breakthrough in the fight against AIDS: two shots a year, 100% effective? Monday Jian

Since the first case of AIDS was reported in the world in 1981, mankind has been fighting AIDS for 40 years. Visual China / Figure

focus

[A new breakthrough in the fight against AIDS: two shots a year, 100% effective? 】

On June 20, 2024, Gilead Sciences, an American biopharmaceutical company, announced on its official website that its "Lenacapavir" (lenacapavir) has shown 100% effectiveness in preventing HIV.

The three-phase, double-blind, randomized trial, called PURPOSE 1, studied more than 5,300 cisgender women and adolescent girls aged 16-25 from 25 locations in South Africa and 3 locations in Uganda.

Subjects were divided into three groups, one group of lenacalpavir who received twice-yearly dosing; the other group was daily oral darcovola, a type of HIV pre-exposure prophylaxis; The third group was daily oral Sufatai (a blocking drug after HIV exposure).

The results showed that among 2134 women in the lenacapavir group, there were 0 cases of HIV infection. Protective efficacy was superior to the other two regimens, and lenacapavir was generally well tolerated, with no significant or new safety concerns identified.

Jianyan: Since the world's first case of AIDS was reported in 1981, mankind's fight against AIDS has lasted for 40 years. AIDS is one of the world's three major public health problems, and every step of progress in the field of drug research and development affects people's hearts. As the most comprehensive and promising clinical trial program for HIV prevention to date, it shows hope that it could help achieve the United Nations General Assembly's goal of ending the AIDS epidemic by 2030.

foodstuff

[Media exposure "stepping on goose intestines" local response has been seized]

On June 17, 2024, the Beijing News reported that the duck intestine workshop of Shandong Yashixiang Meat Food Co., Ltd. and the goose intestine workshop of Henan Qingfeng County Yongguan Food Co., Ltd. have many health and safety hazards in production. The image of stepping on goose intestines and piling duck intestines on the ground and mixing them with detergent-containing sewage is disgusting.

In the afternoon of the same day, the market supervision and management departments of the two companies said that a joint working group had been set up and the production workshops involved in the two companies had been sealed, and the follow-up was further dealt with according to the investigation.

[MANNER coffee shop clerk "out of control" workers "break the defense"]

In just two days, MANNER Coffee was exposed to three conflicts in which baristas poured coffee powder on customers, slapped customers and beat customers.

On the evening of June 21, 2024, MANNER's official Weibo posted that this incident violated the original intention of MANNER's service, apologized to customers, and appeased the barista partners involved, and the company would optimize operational arrangements and improve daily care for baristas.

Jianyan: In 2015, MANNER Coffee was established, with a cup of 15 to 20 yuan and co-branded cooperation with well-known brands, which has become well-known in the field of specialty coffee, and the number of stores has exceeded 1,000. A cup of coffee needs to be made every 3 minutes, and the barista is working too hard. To both low prices and high-quality products, enterprises need to invest more costs in order to achieve sustainable development.

policy

[46 substances were included in the list of fine hemp tube products]

On June 19, 2024, the State Food and Drug Administration issued an announcement stating that in conjunction with the Ministry of Public Security and the National Health Commission, 46 substances such as bromophine, metoniquin, flubrorazepam, and medetomidate will be included in the "Supplementary Catalogue of Controlled Varieties of Non-medical Narcotic Drugs and Psychotropic Substances", which will come into force on July 1, 2024.

Shan Yehua, deputy director of the National Narcotics Control Office and deputy director of the Narcotics Control Bureau of the Ministry of Public Security, said at a press conference held on June 19, 2024 that the addition of new psychoactive substances in China will reach 234.

Jianyan: In recent years, new addictive psychotropic substances have emerged in an endless stream, with strong addiction, and most of them are active in the drug market in the form of camouflage, some abusers do not know the actual type they buy, and it is difficult to grasp the dosage.

Medical Health Insurance

[The National Health Insurance Bureau disclosed the details of insurance fraud in two medical institutions in Henan Province]

On June 23, 2024, the National Health Insurance Administration disclosed that it was preliminarily found that Zhengzhou Guancheng Yufeng Hospital had illegal and illegal problems such as repeated charges and excessive standard charges, involving medical expenses of 1.023 million yuan, and Zhoukou Shangshui Qingkang Hospital had problems such as excessive standard charges, collusion of items, and excessive diagnosis and treatment, involving medical expenses of 768,000 yuan.

Zhengzhou Guancheng Yufeng Hospital has only more than 30 beds, with an average of about 10 patients per day, but more than 8 people are "hospitalized and discharged together" as many as 5 times; For the purpose of insurance fraud, the hospital exchanged medical insurance items, such as self-paid items and consumables such as crown restoration and porcelain teeth, for arthroscopic surgery treatment and included them in medical insurance reimbursement. In addition, the hospital is also suspected of falsifying color ultrasound, X-ray examination reports, and suspected fictitious employee medical insurance outpatient co-ordination services.

Jianyan: In 2024, the National Health Insurance Administration will strengthen the application of big data screening methods in the supervision of medical insurance funds. In advance, the National Health Insurance Administration used a big data model to screen the use of medical insurance funds in the inspected cities, and according to suspicious clues, designated Zhengzhou Guancheng Yufeng Hospital and Zhoukou Shangshui Qingkang Hospital as the inspected institutions, and initially found suspected fraud and insurance fraud. With the blessing of big data and other technical means, all kinds of fraud and insurance fraud will become more and more hidden.

[Beijing Municipal Medical Insurance Bureau: Settlement will be suspended if the medical insurance card is fraudulently used by others]

On June 18, 2024, the Beijing Municipal Health Insurance Bureau issued a notice stipulating that administrative treatment will be made for violations of laws and regulations in the field of medical insurance according to different circumstances.

For example, giving one's medical insurance certificate to someone else to use in an impersonation name; Duplicate medical insurance benefits; In the case of taking advantage of the opportunity to resell drugs with medical insurance benefits, the online settlement of medical expenses shall be suspended for at least 3 months.

If the loss of the medical insurance fund is more than 20,000 yuan, the online settlement of medical expenses will be suspended for 12 months.

Jianyan: For a long time, there are many patients, especially middle-aged and elderly patients, who do not realize that borrowing other people's medical insurance cards is illegal and illegal, and it is not uncommon to prescribe drugs and resell them for profit. The notice clarifies the severity of violations of laws and regulations and the corresponding handling and punishment measures, and the mentality of "the law does not hold the public accountable" can no longer be found.

Anti-rot

[The former director of the Department of Orthopedics of Nanjing First Hospital was investigated]

On June 21, 2024, the Nanjing Municipal Commission for Discipline Inspection and Supervision issued a notice that Yao Qingqiang, the former director of the Department of Orthopedics of Nanjing First Hospital, is suspected of serious violations of discipline and law, and is currently undergoing disciplinary review by the Discipline Inspection and Supervision Team of the Nanjing Municipal Commission for Discipline Inspection and Supervision of the Municipal Health Commission and the supervision and investigation of the Nanjing Gaochun District Supervision Committee.

[Guizhou Provincial Food and Drug Administration officials were investigated after retirement]

On June 17, 2024, according to the Guizhou Provincial Commission for Discipline Inspection and Supervision, Shu Lizhi, the former inspector of the Guizhou Provincial Food and Drug Administration, is suspected of serious violations of discipline and law, and is currently undergoing disciplinary review and supervision investigation by the local Commission for Discipline Inspection and Supervision.

According to public information, Shu Lizhi is 66 years old. He used to be the director of the Guizhou Reporter Station of "Health News", and the former member of the party group and deputy director of the Guizhou Provincial Food and Drug Administration.

Medicines

[InnoCare's CD19 monoclonal antibody combined with lenalidomide was accepted for marketing]

On June 20, 2024, InnoCare, a biopharmaceutical company, announced that the NMPA has accepted the marketing authorization application for the CD19 monoclonal antibody taxitumab in combination with lenalidomide for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation, and will be included in the priority review.

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma (NHL), with an incidence of 45.8% of all non-Hodgkin lymphomas in China, mostly in middle-aged and elderly people, and more common in 40-50 years old. At present, tanxitumab has been approved in the United States, Europe, Hong Kong, China and other places.

Southern Weekly reporter Cui Huiying

Editor-in-charge: Wang Tao